Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 1/20 | 0.55 |
| ▸ | FNTB | P49356 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | MME | P08473 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474296 | 1.00 | CA1 (0.59) | CA1CAPN1FNTAFNTBCTSK | |
| SCHEMBL4487966 | 1.00 | CA1 (0.59) | CA1CAPN1FNTAFNTBCTSK | |
| SCHEMBL3169245 | 1.00 | CA1 (0.59) | CA1CAPN1FNTAFNTBCTSK | |
| SCHEMBL11705090 | 0.91 | FNTA (0.62) | CA1FNTAFNTBCTSKCTSL | |
| SCHEMBL11705092 | 0.91 | FNTA (0.62) | CA1FNTAFNTBCTSKCTSL | |
| SCHEMBL22122399 | 0.89 | CA1 (0.57) | CA1FNTAFNTBCTSKCTSL | |
| SCHEMBL22122396 | 0.89 | CA1 (0.57) | CA1FNTAFNTBCTSKCTSL | |
| SCHEMBL5223065 | 0.88 | CA1 (0.57) | CA1FNTAFNTBCTSKCTSL | |
| SCHEMBL30406651 | 0.88 | CA1 (0.57) | CA1FNTAFNTBCTSKCTSL | |
| SCHEMBL1157282 | 0.88 | FNTA (0.64) | CA1FNTAFNTBCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517879-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2009-04-14 | — | — | US | disclosed |
| US-7429587-B2 | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7326785-B2 | Pyrrolidine derivatives as factor XA inhibitors | GLAXO GROUP LIMITED (GB) | 2008-02-05 | — | — | US | disclosed |
| US-7282497-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
| EP-1839659-A2 | Chemicals compounds | GLAXO GROUP LIMITED (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-07-05 | — | — | US | disclosed |
| US-20070142374-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-06-21 | — | — | US | disclosed |
| US-20070142375-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | CHAN CHUEN | 2007-06-21 | — | — | US | disclosed |
| US-7226929-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1395606-B1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LTD (GB) | 2007-05-02 | — | — | EP | disclosed |
| US-7186717-B2 | Pyrrolidine derivatives as Factor Xa inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7084139-B2 | Pyrrolidin-2-one derivatives as inhibitors of factor Xa | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1395553-B1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2005-02-16 | — | — | EP | disclosed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155745-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | CA1 3405/4885CAPN1 2064/4885FNTA 946/4885 |
| US-20060160885-A1 | drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents | SERPINC1, F11, TFPI | CA1 2501/4885CAPN1 1683/4885FNTA 2010/4885 |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | TFPI, F2, SERPINC1 | CA1 3405/4885CAPN1 2064/4885FNTA 946/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | CA1 2769/4885CAPN1 1786/4885FNTA 1067/4885 |
| US-20060160886-A1 | Synergistic mixtures of 6-Chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide and 4-chloro-N-{1-[1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}-1-benzothiophene-2-sulfonamide; improved oral bioavailability and pharmacokinetics | SULT1E1, SULT1A1, SULT2A1 | CA1 2128/4885CAPN1 470/4885FNTA 1313/4885 |
| US-20070142374-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | CA1 3405/4885CAPN1 2064/4885FNTA 946/4885 |
| US-20070142375-A1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | TFPI, F2, SERPINC1 | CA1 3405/4885CAPN1 2064/4885FNTA 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.